Viking Therapeutics, Inc. (VKTX) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
VKTX currently has 112M outstanding shares. with minimal authorized share overhang for future dilution. The company has minimally diluted shareholders by 3.31% over the past 2 years.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| Jul 23, 2025 |
10-Q filing | 112.1M shares outstanding |
110M | 0 |
| Apr 24, 2025 |
10-Q filing | 112.1M shares outstanding |
110M | 0 |
| Feb 26, 2025 |
10-K filing | 109.0M shares outstanding |
110M | 0 |
| Oct 23, 2024 |
10-Q filing | 110.9M shares outstanding |
110M | 0 |
| Jul 24, 2024 |
10-Q filing | 110.4M shares outstanding |
110M | 0 |
| Apr 25, 2024 |
10-Q filing | 103.5M shares outstanding |
100M | 0 |
| Mar 04, 2024 |
8-K filing: Viking Therapeutics, Inc. closed its underwritten public offering, selling 7,441,650 shares of common stock at $85.00 per share, including the full exercise of the underwriters' option to purchase 970,650 additional shares. |
94M | 6M |
| Mar 01, 2024 |
8-K filing: Viking Therapeutics, Inc. entered into an underwriting agreement for a public offering of 6,471,000 shares of its common stock at a public offering price of $85.00 per share, with an option for the underwriters to purchase an additional 970,650 shares. ($550.0M proceeds) |
94M | 6M |
| Feb 07, 2024 |
10-K filing | 94.3M shares outstanding |
94M | 6M |
| Oct 25, 2023 |
10-Q filing | 99.8M shares outstanding |
100M | 460K |
| Jul 26, 2023 |
10-Q filing | 99.0M shares outstanding |
99M | 1.3M |
| Apr 26, 2023 |
10-Q filing | 99.6M shares outstanding |
100M | 720K |
| Apr 03, 2023 |
8-K filing: Viking Therapeutics, Inc. announced the closing of its underwritten public offering of shares of its common stock, selling 19,828,300 shares at a price of $14.50 per share, including the exercise in full by the underwriters of their option to purchase 2,586,300 additional shares. |
77M | 23M |
| Mar 31, 2023 |
8-K filing: Viking Therapeutics, Inc. entered into an underwriting agreement for a public offering of 17,242,000 shares of common stock at a public offering price of $14.50 per share, with the underwriters having an option to purchase an additional 2,586,300 shares. ($250.0M proceeds) |
77M | 23M |
| Feb 10, 2023 |
10-K filing | 76.8M shares outstanding |
77M | 23M |
| Oct 26, 2022 |
10-Q filing | 76.5M shares outstanding |
77M | 24M |
| Jul 27, 2022 |
10-Q filing | 76.8M shares outstanding |
77M | 23M |
| Apr 27, 2022 |
10-Q filing | 77.4M shares outstanding |
77M | 23M |
| Feb 09, 2022 |
10-K filing | 78.4M shares outstanding |
78M | 22M |
| Nov 03, 2021 |
10-Q filing | 78.2M shares outstanding |
78M | 22M |
| Jul 28, 2021 |
8-K filing: Viking Therapeutics, Inc. entered into an At-The-Market Equity Offering Sales Agreement with Stifel, Nicolaus & Company, Incorporated, Truist Securities, Inc. and H.C. Wainwright & Co., LLC, pursuant to which the Company may offer and sell, from time to time, up to $125.0 million shares of its common stock. |
78M | 22M |
| Jul 28, 2021 |
S-3 filing: Viking Therapeutics, Inc. files an S-3 form to offer and sell up to $600,000,000 in the aggregate of common stock, preferred stock, and debt securities from time to time in one or more offerings and offering of common stock for general research and development, working capital and general corporate purposes. |
78M | 22M |
| Jul 28, 2021 |
10-Q filing | 78.2M shares outstanding |
78M | 22M |
| Apr 28, 2021 |
10-Q filing | 78.1M shares outstanding |
78M | 0 |
| Feb 17, 2021 |
10-K filing | 74.1M shares outstanding |
74M | 0 |
| Oct 28, 2020 |
10-Q filing | 73.0M shares outstanding |
73M | 0 |
| Jul 29, 2020 |
10-Q filing | 72.8M shares outstanding |
73M | 0 |
| Apr 30, 2020 |
10-Q filing | 72.6M shares outstanding |
73M | 0 |
| Feb 26, 2020 |
10-K filing | 72.6M shares outstanding |
73M | 0 |